Displaying 205 (all) recruiting clinical trials.
-
Site for 10144 - A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects
The purpose of the study is to determine if olaparib works in treating patients with urothelial cancer with deoxyribonucleic acid (DNA)-repair defects that has ... -
ANBL19P1: A Pilot Study of Dinutuximab Sargramostim (GM-CSF) and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
The overall goal of this study is to find out whether the combination of the chemotherapy drugs temozolomide and irinotecan with immunotherapy can be given ... -
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The purpose of the study is to determine how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive ... -
A Phase 1 Study of RTX-321 for the Treatment of Patients with Advanced Malignancies Associated with Human Papillomavirus-16 Infection
The purpose of the study is to determine the safety and tolerability of RTX-321 for the treatment of patients that are HLA-A*02:01 (a ... -
A Phase IIa Open-label Clinical Trial to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
The first purpose of this study is to learn if combining the study drug BP1001 with the standard-of-care drugs Venetoclax and decitabine in first line ... -
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
The purpose of the study is to determine how well tucatinib works with trastuzumab for solid tumors that make either more HER2 or a different ... -
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer
The purpose of the study is to evaluate the safety and tolerability of BLU-945, an orally available, highly potent and selective inhibitor of EGFR resistance ... -
A Multi-center Open-label Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL
The purpose of the study is to optimize the dosage of calaspargase pegol in newly-diagnosed Philadelphia-negative acute lymphoblastic leukemia (ALL) patients based on age. We ... -
A phase 4 single-arm open-label clinical study of pembrolizumab (MK-3475) to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent/ metastatic head and neck squamous cell carcinoma.
The purpose of the study is to evaluate the safety, efficacy, and tolerability of combined treatment: pembrolizumab and carboplatin and paclitaxel for patients with recurrent ... -
An Open Label Phase 1 Dose-Escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 with Pembrolizumab Following Radiation Therapy in the Treatment of Non-Small-Cell Lung Cancer Triple-Negative Breast Cancer or Squamous Cell Carcinoma of the Head and Neck that has Progressed on Checkpoint Inhibitors
The purpose of the study is to evaluate the safety, tolerability, and preliminary antitumor activity of TAK-676 and pembrolizumab following radiation therapy in the treatment ...